Top 20 Immunology Companies Based 2019 Immunology Segment Revenue

Immunology is an important branch of science which deals with the study of the immune system. The immune system is a highly regulated and balanced system and when the balance is disturbed- the disease can result. A lot of this work has importance in the development of new therapies and treatments that can handle or heal the condition by modifying the way the immune system is working or- in the case of vaccines- instructing the immune system and enhancing the immune reaction to specific pathogens. In the top 20 ledgers- AbbVie again ensured the top position with total revenue of $19.57B with its blockbuster drug- Humira (adalimumab) from its immunological segment. Our team at PharmaShots has compiled a list of the top 20 immunology companies based on their 2019 immunology revenue

Immunology Segment Revenue: $0.01B

Founded Year: 1979

Market Cap: ~ $0.49B

Total Employees: ~178

Headquarter: New Jersey- United States

Stock Exchange: NASDAQ

Antares Pharma is an American pharmaceutical company focus on developing and commercializing therapies for rheumatology- urology- endocrinology- and neurology. Antares has reported a total sale of $0.01B from its immunology segment in 2019

Immunology Segment Revenue: $0.24B

Founded Year: 2008

Market Cap: ~$15.70B

Total Employees: ~1,200

Headquarters: Dublin- Ireland

Stock Exchange: NASDAQ

Horizon Therapeutics is an Ireland-based biopharmaceutical company focused on developing and commercializing therapies for the treatment of gout- rheumatoid arthritis- and rare diseases. Horizon has generated the sale of $0.24B from its four approved immunology products including Tepezza- Rayos- Duexis and Vimovo. Horizon's Tepezza was selected for the 2020 R&D World R&D 100 Award

Immunology Segment Revenue: $0.49B

Founded Year: 1993

Market Cap: ~$2.57B

Total Employees: ~5,047

Headquarters: Shenyang- China

Stock Exchange: HKD

3SBio is a fully integrated Chinese biotechnology company with market-leading biopharmaceutical franchises in oncology- auto-immune diseases- nephrology- metabolic diseases- and dermatology. There are three approved drugs in its immunology portfolio including Yisaipu- Tpiao and Xenopus. 3SBio's Tpiao used to treat chemotherapy-induced thrombopenia (approved in 2005) and immune thrombocytopenia has generated global sales of $0.33B in 2019.

Immunology Segment Revenue: $0.73B

Founded Year: 1978

Market Cap: ~$42.57B

Total Employees: ~7,400

Headquarters: Massachusetts- United States

Stock Exchange: NASDAQ

Biogen is a global biopharma company focused on neurology- hematologic- and autoimmune diseases. Biogen has a total of six products in its immunology segment with four approved drugs including Tysabri- IMRALDI- FLIXABI- BENEPALI. Biogen's lead drug Tysabri recorded a revenue of $1.89B. Biogen revealed the positive result of BIIB059 in the Phase 2 LILAC study for cutaneous lupus erythematosus and systemic lupus erythematosus.

Immunology Segment Revenue: $0.81B

Founded Year: 2000

Market Cap: ~$88.14

Total Employees: ~99,000

Headquarter: Brentford- United Kingdom

Stock Exchange: LON

GlaxoSmithKline (GSK) is a global healthcare company serving the world with drugs- vaccines & consumer healthcare products. With only approved products- Benlysta- GSK has generated a revenue of $0.81B in 2019. In Jul 2019- GSK initiated the phase 3 study of otilimab for rheumatoid arthritis. In Sep'19- EMA granted a positive CHMP opinion for intravenous Benlysta in children with lupus and was approved in Oct 2019.

Immunology Segment Revenue: $1.11B

Founded Year: 2007

Market Cap: ~$34.6B

Total Employees: ~7,228

Headquarters: Osaka- Japan

Stock Exchange: TYO

Mitsubishi Tanabe is a Japanese pharma company focused on autoimmune diseases- diabetes and kidney diseases- neurological disorders- and vaccines. Mitsubishi has reported a total sale of $1.11B from its immunology segment in 2019.

Immunology Segment Revenue: $1.24B

Founded Year: 1891

Market Cap: ~$197.46B

Total Employees: ~71,000

Headquarters: New Jersey- United States

Stock Exchange: NYSE

Merck & Co. is a global health care company delivering innovative health care products with its Prescription medicines- Oncology drugs- Vaccines- Biologic therapies- and Animal Health care products. Merck has recorded the sale of $1.24B in 2019 from its five approved drugs in its immunology portfolio including Simponi- Remicade- Renflexis- Brenzys- Hadlima. Simponi and Remicade was co-commercialized by Merck and Johnson & Johnson and Simponi recorded the revenue of $0.83B in 2019.

Immunology Segment Revenue: $1.68B

Founded Year: 1991

Market Cap: ~$19.38B

Total Employees: ~1,300

Headquarter: Delaware- United States

Stock Exchange: NASDAQ

Incyte Corp is a global biopharmaceutical firm focused on developing therapies in two categories Oncology and Inflammation & Autoimmune. Incyte has generated a revenue of $1.68B from its immunological segment. In Jan'19- Incyte reports results of Itacitinib in GRAVITAS-301 P-III study for patients with treatment-naive acute graft-versus-host disease.

Immunology Segment Revenue: $1.79B

Founded Year: 2005

Market Cap: ~ $26.49B

Total Employees: ~15,883

Headquarter: Tokyo- Japan

Stock Exchange: TYO

Astellas Pharma is a Japanese multinational pharmaceutical company focused on the therapeutic fields of urology- immunology including transplantation and infectious diseases- oncology- neuroscience and DM complications- and metabolic diseases. Astellas has four drugs in its immunology portfolio including two approved drugs Smyraf And Prograf and has recorded the sale of $1.79B in 2019. In Jul'19- Astellas Pharma launched Smyraf 50 mg and 100 mg tablets for rheumatoid arthritis.

Immunology Segment Revenue: $1.79B

Founded Year: 1901

Market Cap: ~$135.16B

Total Employees: ~33,625

Headquarters: Indiana- United States

Stock Exchange: NYSE

Eli Lilly and Company is a global pharmaceutical firm focused on delivering therapies in two divisions Human Pharmaceutical Products and Animal Health products. The pharmaceutical portfolio offers products for Cardiovascular- Endocrinology- Immunology- Neuroscience- and Oncology. Eli Lilly has two approved drugs including Taltz and Olumiant. Lilly's Taltz- an approved drug for plaque psoriasis or psoriatic arthritis has generated a revenue of $1.6B in 2019. In Apr'19- Eli Lilly signs research and licensing agreement with avidity biosciences to develop therapies in immunology.

Immunology Segment Revenue: $1.92B

Founded Year: 1928

Market Cap: ~$20.49

Total Employees: ~7,600

Headquarters: Brussels- Belgium

Stock Exchange: EBR

UCB is a global biopharmaceutical company focused on neurology- inflammatory- gastrointestinal and autoimmune disorders. UCB has recorded the sale of $1.92B in 2019 from its immunology segment with its only approved drug- Cimzia indicated for psoriatic arthritis (PsA). In Jul'19- Cimzia was approved by China's NMPA.

Immunology Segment Revenue: $2.53B

Founded Year: 1973

Market Cap: ~$122.35B

Total Employees: ~100,000

Headquarter: Paris- France

Stock Exchange: EPA

Sanofi is a global healthcare leader in vaccines providing healthcare solutions in 170+ countries around the world. Sanofi is ranked third in the global market and first in EU and Latin America. Sanofi has four drugs in its immunology portfolio including one approved drug Kevzara- developed in partnership with Regeneron. In Dec'19- Sanofi presented the positive result from its pivoted phase 3 study of sutimlimab for cold agglutinin disease. Additionally- Sanofi restructured its agreement with Regeneron to obtain worldwide rights for Kevzara.

Immunology Segment Revenue: $2.97B

Founded Year: 1887

Market Cap: ~$135.30B

Total Employees: ~30,000

Headquarters: New York- United States

Stock Exchange: NYSE

Bristol-Myers Squibb is an American pharmaceutical company focused on Oncology- Cardiovascular- Immuno-Science- and Fibrosis. BMS has two approved drugs Orencia and Nulojix. BMS' Orencia is a genetically-engineered fusion protein of human CTLA4 and the IgG1 Fc region- indicated to treat adult rheumatoid arthritis- juvenile idiopathic arthritis- and adult psoriatic arthritis has generated the highest revenue of $2.97B in 2019. The acquisition of Celgene in 2019- has boosted up BMS' Immunology pipeline.

Immunology Segment Revenue: $3.66B

Founded Year: 1925

Market Cap: ~$52.60B

Total Employees: ~49,578

Headquarter: Osaka- Japan

Stock Exchange: TYO

Takeda is a global biopharma company focused on Oncology- Gastroenterology (GI)- Neuroscience- Immunology- and Rare Diseases. With three approved drugs including Immunoglobulin- Albumin- and Entyvio- Takeda has generated a $3.66B sale in 2019. In Apr'19- EMA accepted the application for a subcutaneous formulation of Entyvio in Crohn's disease- and in Oct 2019- Takeda acquired CNP-101 from COUR Pharmaceuticals. In Feb'20- Takeda acquired PvP Biologics to strengthen its immunology pipeline. Additionally- Takeda got approval for Entyvio from China's NMPA for Crohn's disease in Mar 2020.

Immunology Segment Revenue: $4.22B

Founded Year: 1996

Market Cap: ~$205.93B

Total Employees: ~109,000

Headquarter: Basel- Switzerland

Stock Exchange: SIX Swiss Exchange- NYSE

Novartis is a group of companies specializing in research- development- manufacturing- and marketing with a broad range of healthcare solutions including generic and ophthalmic therapies. The company is focused on Immunology- Hepatology- Dermatology- Oncology- Neurology- and Ophthalmology. Novartis has the uppermost number of immunology drugs with eight approved products including ACZ885/Ilaris- AIN457/Cosentyx- Myfortic (Renal transplant)- Neoral- Simulect- and Zortress. Novartis Cosentyx (secukinumab) used to treat Psoriasis- ankylosing spondylitis and psoriatic arthritis have generated global sales of $3.55B in 2019. In Apr'19 Novartis acquired IFM Tre to enhance its immunologic portfolio with its NLRP3 inhibitors for $1.5B.

Immunology Segment Revenue: $4.73B

Founded Year: 1849

Market Cap: ~$206.05B

Total Employees: ~83,000

Headquarter: New York- United States

Stock Exchange: NYSE

Pfizer is a research-based- global biopharmaceutical company having a vast portfolio including Oncology- Medicines- vaccines- and other health care products for the prevention & treatment of untreated diseases. With 3 approved drugs including Xeljanz- Enbrel (outside the US and Canada)- and Inflectra (Biosimilar)- Pfizer has generated $4.73B sale from its immunology portfolio indicated for rheumatoid arthritis- psoriatic arthritis- ankylosing spondylitis- Crohn's disease- Behcet's disease- and ulcerative colitis. Pfizer's Xeljanz has generated revenue of $2.24B in 2019. In Jan'2019- CytoReason signed a research partnership with Pfizer to develop drugs using CytoReason's cell-centered models of the immune system.

Immunology Segment Revenue: $5.39B

Founded Year: 1980

Market Cap: ~$134.11B

Total Employees: ~23,400

Headquarter: California- United States

Stock Exchange: NASDAQ

Amgen is one of the leading biotechnology company developing novel therapies focused on cardiology- oncology- neurology- nephrology- and inflammatory diseases. Amgen has generated a total sale of $5.39B in 2019 with its drugs Otezla- Avsola- Enbrel- Nplate- and Prolia. Amgen's Otezla used to treat certain types of psoriasis and psoriatic arthritis has generated sales of $1.6B.

Immunology Segment Revenue: $8.79B

Founded Year: 1896

Market Cap: ~ $281.59B

Total Employees: ~98,000

Headquarter: Basel- Switzerland

Stock Exchange: SWX

Roche Holding AG is a Swiss multinational healthcare company that operates worldwide under two divisions: Pharmaceuticals and Diagnostics. The immunology department focus on rheumatoid arthritis (RA)- systemic juvenile idiopathic arthritis- polyarticular juvenile idiopathic arthritis- and giant cell arteritis including severe persistent allergic asthma (AA)- chronic idiopathic urticaria (CIU)- and idiopathic pulmonary fibrosis (IPF) with 3 approved drugs including Actemra- CellCept and Mabthera and has generated the sale of $8.97B in 2019. In Dec'2019- Roche signed an exclusive global option and license agreement with Rheos Medicines to develop and commercialize therapies for immune metabolism.

Immunology Segment Revenue: $13.95B

Founded Year: 1887

Market Cap: ~$378.94B

Total Employees: ~132,100

Headquarters: New Jersey- United States

Stock Exchange: NYSE

Johnson & Johnson (J&J) is an American multinational healthcare company focused on the development and commercialization of pharmaceutical- medical device- and consumer packaged products. The pharmaceutical portfolio offers products for Cardiovascular- Endocrinology- Immunology- Neuroscience- and Oncology. J&J has generated $13.95B from its Immunology portfolio with 5 approved products including Remicade- Simponi- Stelara- Tremfya- Simponi Aria. Remicade was jointly marketed by J&J and Merck and has generated a revenue of $4.38B in 2019. In Nov 2019- J&J's Tremfya meets the primary endpoint in the phase 3 study for Psoriatic Arthritis. Additionally- J&J submit two applications with the USFDA for Polyarticular Juvenile Idiopathic Arthritis and Juvenile Psoriatic Arthritis. FDA approved Tremfya for Psoriatic Arthritis and Simponi Aria for polyarticular juvenile idiopathic arthritis and active psoriatic arthritis for patients 2 years of age and older in Jul 2020.

Immunology Segment Revenue: $19.57B

Founded Year: 2012

Market Cap: ~$146.29B

Total Employees: ~30,000

Headquarter: Illinois, United States

Stock Exchange: NYSE

AbbVie is a global, research and development-based biopharmaceutical company focused on developing innovative advanced therapies. The company is focused on developing products in immunology, oncology, virology, and neuroscience, dermatology. AbbVie has generated the sale of $19.57B in 2019 from its immunological segment with 3 approved drugs including RINVOQ, SKYRIZI, HUMIRA. AbbVie’s blockbuster drug HUMIRA recorded a revenue of $19.16B. In Apr’2019, AbbVie received EMA approval of SKYRIZI for Plaque Psoriasis. Its RA drug RINVOQ received FDA approval in Aug 2019 and EMA approval in Dec 2019. Additionally, RINVOQ achieved positive results in primary and key secondary endpoints for Psoriatic Arthritis and subsequently submitted the regulatory applications with the FDA and EMA.